Cargando…

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)

Atezolizumab in combination with nab-paclitaxel has been introduced for the treatment of locally advanced or recurrent triple negative breast cancer (TNBC). Patient selection relies on the use of immunohistochemistry using a specific monoclonal PD-L1 antibody (clone SP142) in a tightly controlled co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobritoiu, Florin, Baltan, Adelina, Chefani, Alina, Billingham, Kim, Chenard, Marie-Pierrette, Vaziri, Reza, Lacroix-Triki, Magali, Waydelich, Anne, Erb, Gilles, Andersson, Emilia, Cañamero, Marta, Toro, Paula, Wedden, Sarah, D’Arrigo, Corrado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444286/ https://www.ncbi.nlm.nih.gov/pubmed/36036647 http://dx.doi.org/10.1097/PAI.0000000000001053

Ejemplares similares

A consolidated working classification of gastric cancer for histopathologists (Review)
por: Costache, Simona, et al.
Publicado: (2023)

Use of Prospective Multiplex Immunohistochemistry to Redefine Tissue Pathways of Diagnostic Core Biopsy of Prostate
por: Thomas, Teresa, et al.
Publicado: (2022)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice
por: Losurdo, Agnese, et al.
Publicado: (2020)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting
por: D’Arrigo, Joseph S.
Publicado: (2017)

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood–Brain Barrier
por: D’Arrigo, Joseph S.
Publicado: (2018)

Biomimetic Nanocarrier Targeting Drug(s) to Upstream-Receptor Mechanisms in Dementia: Focusing on Linking Pathogenic Cascades
por: D’Arrigo, Joseph S.
Publicado: (2020)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Secretome and Extracellular Vesicles as New Biological Therapies for Knee Osteoarthritis: A Systematic Review
por: D’Arrigo, Daniele, et al.
Publicado: (2019)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
por: Estrada-Pérez, Alan Rubén, et al.
Publicado: (2022)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Optimization of Short RNA Aptamers for TNBC Cell Targeting
por: Camorani, Simona, et al.
Publicado: (2022)

Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells
por: Consoli, Valeria, et al.
Publicado: (2022)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
por: Carroll, Natalie, et al.
Publicado: (2022)

An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
por: Zhang, Mengqi, et al.
Publicado: (2023)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

Synthesis of Lysophospholipids
por: D’Arrigo, Paola, et al.
Publicado: (2010)

Management of COVID-19 post-vaccine Bell's palsy in an outpatient
por: Cellina, Michaela, et al.
Publicado: (2022)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
por: Camorani, Simona, et al.
Publicado: (2018)

IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?
por: Vagia, Elena, et al.
Publicado: (2020)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
por: Ferrari, Paola, et al.
Publicado: (2022)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC
por: Zhang, Mi, et al.
Publicado: (2022)

Kaiso Protein Expression Correlates with Overall Survival in TNBC Patients
por: Bocian, Artur, et al.
Publicado: (2023)

Inhibition of ERK signaling for treatment of ERRα positive TNBC
por: Musheyev, David, et al.
Publicado: (2023)

Core promoter in TNBC is highly mutated with rich ethnic signature
por: Huang, Teng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s0pdq9qnvuv68bjdbguc7blf4h